Investor Relations Representative
Vice President, Investor Relations
Replay available
Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call
Capricor Therapeutics, Inc. (NASDAQ: CAPR) Q4 2025 earnings conference call, held 2026-03-12. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Linda Marbán
Chief Executive Officer
A.J. Bergman
Chief Financial Officer
Ted Tenthoff
Analyst, Piper Sandler
Leland Gershel
Analyst, Oppenheimer & Co.
Joe Pantginnis
Analyst, H.C. Wainwright & Co.
Kristen Kluska
Analyst, Cantor Fitzgerald
Katherine Novak
Analyst, JonesTrading
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Capricor Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.355 Good afternoon, ladies and gentlemen, and welcome to the Capricorn Therapeutics fourth 00:00:04.355 -- 00:00:08.079 quarter and full year 2025 conference call. 00:00:08.079 -- 00:00:11.662 At this time, all participants are in a listen-only mode. 00:00:11.662 -- 00:00:15.466 Following the presentation, we will conduct a question and answer session. 00:00:15.466 -- 00:00:20.010 If at any time during this call you require immediate assistance, please press star zero 00:00:20.010 -- 00:00:25.055 for the operator. This call is made recorded today, Thursday, March 00:00:25.055 -- 00:00:27.301 12, 2026. 00:00:27.301 -- 00:00:31.887 I would now like to turn the conference over to CFO AJ Bergman for the forward looking 00:00:31.887 -- 00:00:35.449 statement. Please go ahead, sir. 00:00:36.452 -- 00:00:38.795 Thank you and good afternoon, everyone. 00:00:38.795 -- 00:00:42.400 Before we start, I would like to state that we will be making certain forward looking 00:00:42.400 -- 00:00:46.685 statements during today's presentation. Statements may include statements regarding, 00:00:46.685 -- 00:00:51.551 among other things, the efficacy, safety, and intended utilization of our product candidates, 00:00:51.551 -- 00:00:55.917 our future R&D plans, including our anticipated conduct and timing of preclinical and 00:00:55.917 -- 00:01:00.700 clinical studies, enrollment of patients in our clinical studies, our plans to present 00:01:00.700 -- 00:01:05.474 or report additional data, our plans regarding regulatory filings, potential regulatory 00:01:05.474 -- 00:01:09.827 developments involving our product candidates, potential regulatory inspections, revenue 00:01:09.827 -- 00:01:14.229 and reimbursement estimates, projected terms of definitive agr...